Swedish private health economics institute specialising in HTA, evidence gap analysis, and big data-driven health outcomes research.
IHE (Swedish Institute for Health Economics) is a specialist research company focused on health economics, health technology assessment (HTA), and evidence synthesis for healthcare decision-making. Their core work involves economic modeling, cost-effectiveness analysis, and real-world evidence generation that helps payers, regulators, and healthcare systems decide which treatments, diagnostics, and interventions are worth funding. In H2020, they contributed health economics and outcomes research (HEOR) expertise to large multi-stakeholder data initiatives — bringing the "does it work AND is it worth it?" perspective to big data and clinical research consortia. They operate at the intersection of clinical evidence and health policy, translating scientific findings into economic arguments that reach decision-makers.
IHE's core institutional identity as a health economics institute underpins their contribution to both DO-IT and PIONEER, where outcomes data and evidence gaps are central deliverables.
Both projects (DO-IT and PIONEER) explicitly center on big data-driven approaches to healthcare transformation and cancer diagnosis, with IHE providing the outcomes-research lens.
PIONEER lists 'critical evidence gaps' and 'research prioritisation' as direct keywords, reflecting IHE's typical role in mapping what evidence is missing and where investment should go.
PIONEER's keywords include 'genetic profile' and 'natural history', suggesting IHE contributed to evidence frameworks around observational and registry-based data for prostate cancer.
DO-IT's full title explicitly targets 'Policy Innovation and Healthcare System Transformation', positioning IHE as an actor in health system reform through data-driven policy tools.
IHE entered H2020 through DO-IT (2017), a broad healthcare system transformation project with no granular keyword footprint in the data, suggesting a wide-scope, foundational role in health economics methodology. By PIONEER (2018), their contribution sharpened considerably — keywords point to specific analytical tasks: identifying evidence gaps, prioritising research questions, and working with multidisciplinary data sources including genetic and natural history data in prostate cancer. The arc is from general health economics consulting in system-level projects toward more targeted evidence synthesis work in disease-specific, data-intensive research programmes.
IHE is moving toward precision health economics — applying evidence synthesis and research prioritisation to specific disease areas underpinned by real-world and genomic data, which aligns with the growing IMI and European health data infrastructure agenda.
IHE exclusively participates in consortia as a partner and has never coordinated an H2020 project, which is typical for specialist advisory organisations brought in for their methodological niche rather than project management capacity. Despite only two projects, they have accumulated 63 unique consortium partners across 16 countries — a strong signal that both projects were large IMI-type mega-consortia where IHE played a defined specialist role. This makes them a reliable, low-friction partner: they know how to operate inside complex multi-partner structures without needing to lead them.
IHE has built a notably wide network — 63 unique partners across 16 countries — from just two projects, which reflects participation in large Innovative Medicines Initiative (IMI) consortia that typically bring together pharma companies, hospitals, universities, and HTA bodies across Europe. Their network is pan-European with no evident geographic concentration beyond their Swedish base.
IHE is one of very few independent, private health economics institutes in Scandinavia with demonstrable EU project experience — most HTA work in this space is done by academic units or government agencies. As a private SME, they can move faster and engage commercially with pharma, medtech, and payer organisations in ways that university partners cannot. Their combination of rigorous economic methodology and applied policy relevance makes them the right partner when a consortium needs to bridge clinical research and healthcare system adoption.
